stoxline Quote Chart Rank Option Currency Glossary
  
Soligenix, Inc. (SNGX)
7.68  0.03 (0.39%)    07-12 14:58
Open: 7.26
High: 8.25
Volume: 1,199,592
  
Pre. Close: 7.65
Low: 7.1
Market Cap: 8(M)
Technical analysis
2024-07-12 2:24:38 PM
Short term     
Mid term     
Targets 6-month :  11.52 1-year :  17.32
Resists First :  9.86 Second :  14.82
Pivot price 3.93
Supports First :  1.83 Second :  1.52
MAs MA(5) :  6.48 MA(20) :  3.94
MA(100) :  7.17 MA(250) :  8.41
MACD MACD :  0.4 Signal :  -0.3
%K %D K(14,3) :  44.9 D(3) :  40.1
RSI RSI(14): 73.6
52-week High :  32 Low :  1.83
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SNGX ] has closed below upper band by 8.9%. Bollinger Bands are 222% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.54 - 8.58 8.58 - 8.63
Low: 6.23 - 6.27 6.27 - 6.3
Close: 7.58 - 7.66 7.66 - 7.73
Company Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Headline News

Tue, 09 Jul 2024
Soligenix stock soars 300% on positive HyBryte study results (NASDAQ:SNGX) - Seeking Alpha

Tue, 09 Jul 2024
Why Is Soligenix (SNGX) Stock Up 296% Today? - InvestorPlace

Tue, 09 Jul 2024
SNGX - Soligenix, Inc. Latest Stock News & Market Updates - StockTitan

Tue, 09 Jul 2024
Soligenix Announces Interim Results for Extended HyBryte™ Treatment in Early-Stage CTCL Patients - Quantisnow

Tue, 09 Jul 2024
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - PR Newswire

Fri, 31 May 2024
Soligenix Announces Reverse Stock Split - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 1 (M)
Held by Insiders 985250 (%)
Held by Institutions 0 (%)
Shares Short 41 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.66e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 809 %
Return on Equity (ttm) -50 %
Qtrly Rev. Growth 699210 %
Gross Profit (p.s.) -29.15
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -9.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -8 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.3
Price to Book value 0
Price to Sales 0
Price to Cash Flow 12.19
Stock Dividends
Dividend 0
Forward Dividend 39940
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android